BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo
BridgeBio:Attribute-Cm研究顯示,與安卡拉米德治療相比,30個月內複合ACm和複發性Cvh事件減少42%。
BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo
BridgeBio:Attribute-Cm研究顯示,與安卡拉米德治療相比,30個月內複合ACm和複發性Cvh事件減少42%。
譯文內容由第三人軟體翻譯。